Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | euchromatic histone-lysine N-methyltransferase 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Onchocerca volvulus | Get druggable targets OG5_131470 | All targets in OG5_131470 | |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Trichomonas vaginalis | set domain proteins, putative | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Brugia malayi | Pre-SET motif family protein | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0251 | 0.0413 | 1 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0072 | 0.007 | 0.5 |
Trypanosoma brucei | 2OG-Fe(II) oxygenase superfamily, putative | 0.0072 | 0.007 | 0.5 |
Onchocerca volvulus | 0.0286 | 0.0479 | 1 | |
Trypanosoma brucei | 2OG-Fe(II) oxygenase superfamily, putative | 0.0072 | 0.007 | 0.5 |
Schistosoma mansoni | nucleic acid binding | 0.0072 | 0.007 | 1 |
Onchocerca volvulus | Alkylated DNA repair protein alkB homolog | 0.0072 | 0.007 | 0.1454 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0072 | 0.007 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.5253 | 1 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0072 | 0.007 | 0.5 |
Echinococcus granulosus | nucleic acid binding | 0.0072 | 0.007 | 1 |
Brugia malayi | ALKBH protein | 0.0072 | 0.007 | 0.1689 |
Mycobacterium ulcerans | hypothetical protein | 0.5253 | 1 | 0.5 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0072 | 0.007 | 0.5 |
Loa Loa (eye worm) | ALKBH protein | 0.0072 | 0.007 | 0.1689 |
Brugia malayi | hypothetical protein | 0.0072 | 0.007 | 0.1689 |
Plasmodium vivax | SET domain protein, putative | 0.0036 | 0 | 0.5 |
Loa Loa (eye worm) | spermatogenesis associated 11 | 0.0072 | 0.007 | 0.1689 |
Trypanosoma brucei | 2OG-Fe(II) oxygenase superfamily, putative | 0.0072 | 0.007 | 0.5 |
Echinococcus granulosus | alkylated DNA repair protein alkB | 0.0072 | 0.007 | 1 |
Trypanosoma brucei | 2OG-Fe(II) oxygenase superfamily, putative | 0.0072 | 0.007 | 0.5 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0072 | 0.007 | 0.5 |
Brugia malayi | spermatogenesis associated 11 | 0.0072 | 0.007 | 0.1689 |
Leishmania major | hypothetical protein, conserved | 0.0072 | 0.007 | 0.5 |
Trypanosoma brucei | 2OG-Fe(II) oxygenase superfamily, putative | 0.0072 | 0.007 | 0.5 |
Onchocerca volvulus | 0.0072 | 0.007 | 0.1454 | |
Loa Loa (eye worm) | hypothetical protein | 0.0072 | 0.007 | 0.1689 |
Leishmania major | hypothetical protein, conserved | 0.0072 | 0.007 | 0.5 |
Echinococcus multilocularis | conserved hypothetical protein | 0.0072 | 0.007 | 1 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0072 | 0.007 | 0.5 |
Echinococcus multilocularis | nucleic acid binding | 0.0072 | 0.007 | 1 |
Brugia malayi | Pre-SET motif family protein | 0.0251 | 0.0413 | 1 |
Trypanosoma brucei | Alkylated DNA repair protein (alkB homolog), putative | 0.0072 | 0.007 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0072 | 0.007 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0072 | 0.007 | 1 |
Trypanosoma cruzi | alkylated DNA repair protein, putative | 0.0072 | 0.007 | 0.5 |
Onchocerca volvulus | 0.0072 | 0.007 | 0.1454 | |
Toxoplasma gondii | hypothetical protein | 0.0072 | 0.007 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0072 | 0.007 | 0.1689 |
Schistosoma mansoni | nucleic acid binding | 0.0072 | 0.007 | 1 |
Trichomonas vaginalis | set domain proteins, putative | 0.0286 | 0.0479 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.2944 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 5.8584 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 32.6294 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.